SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
May 26, 2005
HALOZYME THERAPEUTICS, INC.
|(State or other jurisdiction
|11588 Sorrento Valley Road, Suite 17, San Diego, California||92121|
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (858) 794-8889
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On May 26, 2005, Halozyme Therapeutics, Inc. announced that the U.S. Food and Drug Administration accepted for filing its new drug application (NDA) for HylenexÔ. The press release announcing the acceptance of the NDA is attached hereto as Exhibit 99.1 and is incorporated by reference.
Item 9.01 Financial Statements and Exhibits.
|Press Release dated May 26, 2005.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Halozyme Therapeutics, Inc.
|May 26, 2005||By:||/s/ David A. Ramsay|
|David A. Ramsay|
|Secretary and Chief Financial Officer|